Aurinia Pharmaceuticals Inc. (AUPH)
Summary
Aurinia (AUPH) Upgraded to Strong Buy: Here's Why
Aurinia (AUPH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Aurinia (AUPH) Moves 6.5% Higher: Will This Strength Last?
Aurinia (AUPH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Aurinia: Cash-Generating Today, Pipeline-Driven Tomorrow
Aurinia Pharmaceuticals (AUPH) is positioned for profitable growth, driven by Lupkynis and pipeline expansion via the Kezar Life Sciences acquisition. AUPH delivered strong 1Q26 results: 24% revenue growth, 48% net income growth, and robust cash flow, reaffirming FY26 guidance for double-digit revenue gains. Tang Capital Management increased its stake above 10%, signaling confidence in AUPH's valuation and future pipeline or strategic optionality.
Aurinia Pharmaceuticals Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| CE Curtis Ellergodt Rothschild Investment LLC | 299 | $2,836.05 | $4,721.18 | $1,885.13 | 66.47% |
| ABB Alexander Bjornager Bonde Danske Bank A/S | 300 | $4,785 | $4,736.97 | -$48.03 | -1% |
| BG Bart Gancher Intech Investment Management LLC | 34,945 | $289,777.82 | $554,716.93 | $264,939.11 | 91.43% |
| YA Yinka Akinsola Blue Trust Inc. | 690 | $5,547.6 | $10,972.79 | $5,425.19 | 97.79% |
 Jeff Ameen Spire Wealth Management | 672 | $5,553.64 | $10,819.2 | $5,265.56 | 94.81% |
Aurinia Pharmaceuticals Inc. (AUPH) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Aurinia Pharmaceuticals Inc. ever had a stock split?
Aurinia Pharmaceuticals Inc. Profile
| Biotechnology Industry | Healthcare Sector | Kevin C. Tang CEO | NASDAQ (NMS) Exchange | 05156V102 CUSIP |
| CA Country | 128 Employees | - Last Dividend | 23 Oct 2013 Last Split | 26 Jan 1999 IPO Date |
Overview
Aurinia Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company established in 1993 and based in Edmonton, Canada. The company dedicates its efforts to developing and commercializing innovative therapies intended to address diseases with significant unmet medical needs within the United States. Through its focus on specialized medication, Aurinia Pharmaceuticals has positioned itself as a key player in the healthcare industry, particularly in the realm of treatment for complex diseases. Its partnership with Otsuka Pharmaceutical Co., Ltd. underlines its commitment to expanding its reach and enhancing the impact of its therapeutic solutions on patients' lives.
Products and Services
- LUPKYNIS - This product is designed for the treatment of adult patients suffering from active lupus nephritis, a serious autoimmune disease that affects the kidneys. Aurinia Pharmaceuticals has successfully brought LUPKYNIS to the commercial stage, offering hope and a much-needed solution to individuals dealing with this challenging condition. The availability of LUPKYNIS underscores the company's focus on addressing diseases that have historically had limited treatment options.
